| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3284647 | Clinical Gastroenterology and Hepatology | 2008 | 8 Pages |
Abstract
This phase 2 study was suggestive of a dose-dependent beneficial effect of MLN0002 therapy on clinical remission. MLN0002 was well tolerated in patients with active Crohn's disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N. Fedorak, Pierre Paré, John W.D. McDonald, Albert Cohen, Alain Bitton, Jeffrey Baker, Réjean Dubé, Steven B. Landau, Margaret K. Vandervoort, Asit Parikh,